Marinomed Biotech AG (FRA:93Z)

Market Cap	26.13M +1.3%
Revenue (ttm)	9.76M +47.4%
Net Income	9.12M
EPS	5.13
Shares Out	n/a
PE Ratio	2.87
Forward PE	1.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	63
Open	13.20
Previous Close	12.95
Day's Range	13.20 - 13.20
52-Week Range	11.25 - 21.10
Beta	n/a
RSI	27.07
Earnings Date	Apr 22, 2026

About Marinomed Biotech AG

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development a...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 33
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 93Z

Financial Performance

In 2024, Marinomed Biotech AG's revenue was 4.79 million, a decrease of -49.01% compared to the previous year's 9.40 million. Losses were -15.42 million, 142.2% more than in 2023.